CD163 and metabolic dysfunction-associated steatotic liver disease: Validation analyses showed that the expression of CCR1 and CD163 were consistently and significantly decreased in both HF datasets (GSE26887 and GSE57345) and in both NAFLD datasets (GSE126848 and GSE89632) (Figures 5A–D).